Collectively, the in vitro and in vivo data suggest that EZH2 inhibition by DZNep attenuates TGF-β/SMAD signaling in HSCs, inhibits HSCs activation, mitigates hepatic ECM accumulation and eventually ameliorates liver fibrosis. This evidence concerns the gene EZH2 and Hepatic fibrosis.